Gland Pharma’s profit after tax increased 58% in the quarter ended Sept. 30, as revenue climbed 23.3%, with growth reported in both of its main business lines.
The unaudited consolidated results, approved Nov. 6, showed profit of ₹2,907.56 million, up from ₹1,836.84 million in the year-earlier quarter. Revenue from operations reached ₹18,335.88 million, compared with ₹14,868.75 million. On a sequential basis, profit fell from ₹3,169.59 million in the preceding quarter, while revenue rose from ₹18,002.71 million.
The company reported earnings before interest, taxes, depreciation and amortization (EBITDA) of ₹4,804 million, a 53% annual increase. EBITDA margin expanded to 26% from 21%. Adjusted EBITDA rose 50% to ₹5,030 million, with a margin of 27%.
Contract development and manufacturing organization (CDMO) revenue grew 31% to ₹8,227 million and represented 45% of revenue. Critical Injectables revenue increased 18% to ₹10,109 million, or 55% of the total. Gland Pharma’s filing classifies pharmaceuticals as one reportable business segment, while its earnings release provides separate revenue figures for these businesses.
By geography, U.S. revenue rose 42% year over year to ₹11,795 million. Revenue declined 42% in India to ₹387 million, 18% in Canada, Australia and New Zealand to ₹400 million, and 21% in the rest of the world to ₹2,044 million.
Executive Chairman Srinivas Sadu said more customer activity, strategic partnerships and prospective projects supported the CDMO business. The company also reported research and development spending of ₹1,077 million for the quarter. It attributed broader growth to execution across its businesses and cited manufacturing investment and capacity expansion among its plans.
Mint reported that shares opened at ₹3,147 on the National Stock Exchange of India on Nov. 9 and reached an intraday high of ₹3,352. Mint described that level as a 52-week high.
